

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **GNA11 RABBIT PAB**

货号: S216518

产品全名: GNAll 兔多抗 基因符号 GNA-ll

UNIPROT ID: P29992 (Gene Accession - BC096225)

背景: Guanine nucleotide-binding protein subunit alpha-11 is a protein that in humans is encoded by the GNA11 gene. Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Acts as an activator of phospholipase C.

抗原: Fusion protein of human GNA11 经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 500-2000;ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Signal Transduction

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




## **Product Description**


Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 216518(GNA11 Antibody) at a dilution of 1/40(cytoplasm).




In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 216518(Anti-GNA11 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffinembedded Human lung cancer tissue using 216518(Anti-GNA11 Antibody) at a dilution of 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human lung cancer tissue is first treated with fusion protein and then with D220645(Anti-GNA11 Antibody) at dilution 1/40.



Gel: 10%SDS-PAGE, Lysate: 40 µg; Lane: Human leiomyosarcoma tissue; Primary antibody: 216518(GNA11 Antibody) at dilution 1/450; Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution; Exposure time: 5 minutes



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010